Cinpanemab

Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2].

Product Specifications

CAS Number

[2094516-02-4]

Product Name Alternative

BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)

UNSPSC

12352203

Target

α-synuclein

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cinpanemab.html

Purity

99.0

Solubility

H2O

Smiles

[Cinpanemab]

Molecular Weight

(146.98 kDa)

References & Citations

[1]Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387 (5) :408-420. |[2]Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20 (9) :802-813.